Bayer | Pharmaceuticals

+++ News +++ The U.S. FDA grants Priority Review designation to a new therapy for adult patients living with a common form of heart failure. Approximately 6.7 million people in the U.S. have heart failure, and more than half of these patients suffer from HF with an LVEF of ≥40%, which is associated with substantial morbidity and mortality. However, limited approved and guideline-directed treatments are currently available. Learn more: https://lnkd.in/ekY-krjA

At our annual Pharma Media Day, we showcased the latest advancements in oncology, cardiovascular care and women’s health and more, demonstrating our commitment to R&D and commercial excellence. See how our team is shaping the future of healthcare! #TeamBayer #PharmaMediaDay #PMD25

+++ #News +++ #TeamBayer starts new study for innovative cancer treatment with first patient Together with Vividion Therapeutics, Inc., we have successfully dosed the first patient in Phase I clinical trial with an investigational oral inhibitor targeting RAS-driven cancers. This therapy aims to improve patient outcomes by selectively inhibiting the RAS-PI3Kα signaling pathway, which is crucial in solid tumor development. With approximately 20% of all cancers driven by RAS mutations, this milestone represents our commitment to advance research in #PrecisionOncology for patients battling difficult-to-treat cancers. Learn more: http://spr.ly/6046Fw0Q6 #TeamBayer

Feeling incredibly proud, moved and inspired by the powerful lineup of leaders, partners and patients who presented at our Bayer | Pharmaceuticals Media Day 2025. Following yesterday’s Innovation Expo – an exploration of our pioneering breakthroughs in Data Science, AI-powered Drug Development and Cell & Gene therapy – today’s session provided fascinating insights into how we are: • Unlocking Innovation by driving collaboration and productivity in R&D and Commercialization; • Striving to combat heart failure by paving new ground in cardiovascular care; • Advancing precision oncology by driving breakthroughs in cancer care; • Addressing unmet needs for women by pioneering progress in menopause management. In a landmark year of product launches for Bayer, I would like to thank the record number of journalists who travelled from all corners of the world to engage with our leaders and experience our live event. I very much enjoyed the interactions and discussions with you all. Finally, a huge thank you and kudos to our org team for pulling off another stunning event! #HealthForAll #HungerForNone Treat the Untreatable | Cure Disease | Offer Hope

+++ A landmark launch year for Bayer Pharmaceuticals +++ Today, at our annual Pharma Media Day, we showcased significant advancements in our long-term growth strategy, as part of the ongoing transformation of our pharmaceuticals business. #TeamBayer #PharmaMediaDay #PMD25

We’re excited to share that in Germany, the first patients can receive a new heart drug for "transthyretin amyloid cardiomyopathy," expanding the choice of treatment options for doctors and patients.   This condition is rarely diagnosed or often recognized too late. On average, patients wait over three years for a diagnosis — time that's precious and critical. Anne Effertz suffers from this rare and fatal condition. She lives just a short distance from our #TeamBayer offices. It’s stories like hers that motivate us to keep raising awareness, researching, and offering innovative therapies that target the root causes of rare diseases – providing hope to those in need. #HealthForAll #HungerForNone 

Excellent to see our partnership with Bayer | Pharmaceuticals flourish. Onwards and upwards! 👏

From oncology to cardiovascular diseases, women’s health and beyond, we’re working tirelessly to tackle some of the most pressing health challenges of our time. Through our emphasis on R&D and commercial excellence, we’re advancing programs with the potential to reshape treatment outcomes and meet the unmet needs of patients worldwide. #TeamBayer #PharmaMediaDay #PMD25

Today marks another step in our journey to provide options for cancer patients facing dire prognoses, with little to no effective treatment options. We have entered into a global license agreement with Puhe BioPharma for an innovative MTA-cooperative PRMT5 inhibitor. This oral, small molecule agent targets MTAP-deleted tumors, a significant area of unmet medical need affecting 10-30% of all cancers, including pancreatic and glioblastoma.   We can’t wait to explore the potential of this groundbreaking investigational treatment which could bring hope to those who need it most.   Stay tuned for our progress at #TeamBayer 

+++ #News +++ #TeamBayer Strengthens Precision Oncology Pipeline We are excited to partner with Puhe BioPharma and have started a global phase I clinical study leveraging a highly selective mechanism of action for tumors lacking the MTAP gene, which affects 10-30% of all cancer patients. Our targeted approach encompasses the PRMT5 inhibitor that aims at blocking a specific protein that cancer cells need to grow, allowing it to attack the cancer while aiming at leaving normal cells unharmed. Our commitment to advancing research means for us bringing hope for patients and redefine the future of cancer treatment. Learn more: http://spr.ly/6044079Vw #HealthForAll #HungerForNone